Etese-r.

A follow-on component of the BLAZE-1 trial demonstrates a significant reduction in SARS-CoV-2 viral load at 11 days when bamalinivimab is used in combo with etesevimab, another monoclonal antibody that binds a different epitope to neutralize bam-resistant variants. Clinical benefits remain TBD. | Gottlieb, JAMA 2021

Comments

Popular Posts